Date: 2017-05-10
Type of information: Capital increase
Company: Lonza (Switzerland)
Investors:
Amount: CHF 2.251 billion
Funding type: capital increase
Planned used:
- The gross proceeds from the rights issue will be used to partially finance the acquisition of Capsugel.
Others:
- • On May 10,2017, In connection with the capital increase by way of a rights offering as approved by the shareholders at Lonza's Annual General Meeting on 25 April 2017, Lonza offered a total of 16,548,612 newly issued shares to its existing shareholders. By the end of the rights exercise period on 10 May 2017, , 99.25% of the rights had been exercised, corresponding to 16,424,010 newly issued shares. The 124,602 newly issued shares for which rights have not been exercised will be sold to the market.
- The number of registered shares of Lonza after completion of the rights offering will amount to 74,468,752.
- • On April 25, 2017, Lonza announced that the Board of Directors determined the final terms of the capital increase by way of a rights offering. The Annual General Meeting approved an ordinary capital increase by the issuance of up to 22,000,000 fully paid registered shares by way of a rights offering. The Board of Directors decided to offer 16,548,612 newly issued shares with a nominal value of CHF 1.00 each at an offer price of CHF 136.00, which corresponds to gross proceeds of CHF 2.251 billion. The gross proceeds, net of certain costs and expenses associated with the offering, will be used to partially finance the acquisition of Capsugel.
- The nominal amount of Lonza's issued share capital will be increased from currently CHF 57,920,140 to CHF 74,468,752.
Therapeutic area: Technology - Services
Is general: Yes
